Chemomab Therapeutics Ltd. (CMMB)
| Market Cap | 13.82M -25.6% |
| Revenue (ttm) | n/a |
| Net Income | -7.45M |
| EPS | -1.07 |
| Shares Out | 7.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,461 |
| Open | 1.920 |
| Previous Close | 1.900 |
| Day's Range | 1.870 - 2.040 |
| 52-Week Range | 1.350 - 4.120 |
| Beta | 0.66 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About CMMB
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and i... [Read more]
Financial Performance
Financial StatementsNews
Chemomab Therapeutics Transcript: M&A announcement
The merger creates a precision medicine leader in RA by combining AI-driven diagnostics with a novel anti-CCL24 antibody, supported by $30M in new funding and a de-risked clinical strategy. The combined company targets a major unmet need in RA, with Phase II data expected in 2028.
Chemomab Therapeutics Press release: M&A announcement
Chemomab Therapeutics issued a press release on July 8, 2026, disclosing material business information to investors.
Chemomab Therapeutics Slides: M&A announcement
Chemomab Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 8, 2026.
Chemomab Therapeutics, Scipher Medicine announce merger agreement
Chemomab Therapeutics (CMMB) and Scipher Medicine announced that they have entered into a definitive merger agreement pursuant to which the companies will combine in a stock transaction. Upon completi...
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
Chemomab and Scipher announced a merger agreement to advance nebokitug into a Phase 2 precision medicine trial for the treatment of rheumatoid arthritis.
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Addition...
Chemomab Therapeutics Earnings release: Q1 2026
Chemomab Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Chemomab Therapeutics sees cash runway through 1Q27
Cash, cash equivalents and short-term bank deposits were $10.4 million as of December 31, 2025 compared to $14.3 million as of December 31, 2024. The current cash runway is expected…
Chemomab Therapeutics reports FY25 EPS (1c) vs. (4c) last year
“2025 was a critical year for Chemomab and our nebokitug program,” said Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab. “Our Phase 2 SPRING trial data, viewed by…
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance along with preparations to launch the PSC Phase 3 trial.
Chemomab Therapeutics Annual report: Q4 2025
Chemomab Therapeutics has published its Q4 2025 annual report on March 19, 2026.
Chemomab Therapeutics Earnings release: Q4 2025
Chemomab Therapeutics released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Chemomab Therapeutics Slides: Corporate presentation
Chemomab Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 1, 2026.
Chemomab Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Nebokitug is advancing to phase III for PSC after strong phase II results, with plans to focus on moderate to advanced patients and pursue partnerships for commercialization. The drug also shows promise in systemic sclerosis, targeting a combined market opportunity exceeding $2.5 billion.
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammato...
Chemomab Therapeutics announces results of its Phase 2 SPRING trial
Chemomab Therapeutics (CMMB) announced that the results of its Phase 2 SPRING trial assessing nebokitug in patients with primary sclerosing cholangitis, PSC, were published in the current issue of the...
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a P hase 3 Registration Trial — TEL AVIV...
Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit
TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammato...
Chemomab Therapeutics Earnings release: Q3 2025
Chemomab Therapeutics released its Q3 2025 earnings on November 21, 2025, summarizing the period's financial results.
Chemomab Therapeutics reports Q3 EPS (0.4c) vs (1c) last year
“In the third quarter of 2025 we focused on advancing preparations for the nebokitug Phase 3 trial in patients with primary sclerosing cholangitis, continuing our very productive discussions with the…
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a Clinic...
Chemomab announces presentations at AASLD 2025 on nebokitug data
Chemomab Therapeutics (CMMB) announced that abstracts that highlight new clinical data from the nebokitug Phase 2 SPRING trial in primary sclerosing cholangitis, PSC, will be presented on November 10,...
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
Chemomab announced three presentations "of distinction" at AASLD The Liver Meeting® 2025 featuring clinical data from the nebokitug Phase 2 trial in PSC.
Chemomab Therapeutics management to meet with Maxim
Meeting to be held on September 15-16 hosted by Maxim.
Chemomab Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Positive phase II results for nebokitug in PSC showed strong anti-inflammatory and anti-fibrotic effects, with FDA alignment for a single pivotal phase III study. The drug is positioned as a potential first-in-class, disease-modifying therapy with significant commercial potential.